- Home
- BNZI vs VRAX Comparison
BNZI vs VRAX Comparison
Compare BNZI & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNZI | VRAX |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 2.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | BNZI | VRAX |
|---|---|---|
| Price | $1.22 | $0.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $23.00 | $1.00 |
| AVG Volume (30 Days) | ★ 1.0M | 485.7K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,650,176.00 | $2,986.00 |
| Revenue This Year | $185.61 | $217,274.83 |
| Revenue Next Year | $32.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.06 | N/A |
| 52 Week Low | $0.92 | $0.26 |
| 52 Week High | $27.00 | $2.33 |
Technical Indicators
Market Signals| Indicator | BNZI | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 33.03 |
| Support Level | $1.21 | $0.26 |
| Resistance Level | $1.38 | $0.30 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 24.48 | 9.38 |
Price Performance
Historical ComparisonAbout BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).